Search Results

The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 5, 2024, the Institut National d’Excellence en Santé et en Services Sociaux (INESSS) recommended Columvi® (glofitamab for injection) for public reimbursement.

NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when combined with Tecentriq did not significantly boost overall survival in non-small cell lung cancer.

Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases.

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage win in relapsing multiple sclerosis, demonstrating near-total elimination of disease activity.

When doses were increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal distension.